San Diego healthtech Real Time Location System provider Awarepoint goes 404. bit.ly/2JuDnzl

Diego Miralles: Illumina has been able to stay in San Diego because you have been able to continue to innovate. How is it that Illumina manages to keep that innovation machine going as a big company? Diego Miralles #vividion #sdxcon2022 #sandiego #biotech

"In the not too distant future we are looking at receiving samples from critically ill newborns from childrens' hospitals all over the country." Shimul Chodhurry, Clinical Lab Director at Rady Pediatric Genomic and Systems Medicine Institute. #sdxcon2022 #sandiego #biotech

Rich Heyman: Since my time in San Diego as a postdoc at the Salk Institute, I've had the good fortune and opportunity to go to work at companies that were commercializing new technology. #sdxcon2022 #sandiego #biotech

Rich Heyman: We are impacted by two huge global issues: A tremendous increase in global population, and feed those people and provide water. Future wars are not going to be fought over territory but over food and water. In the scientific community we need to think about this...

Rich Heyman: Another major issue is climate change and global warming. At the Salk Institute, we have a team that is working to engineer plants to suck more carbon dioxide out of the atmosphere.

Rich Heyman: "The way academic research gets funded, the way biotechs get funded, the way big pharma gets funded... needs to evolve. We need new models that provide a better interface between academics, startup companies, and what happens at big pharma." #sdxcon2022 #sandiego

Surprise guest: Salk Institute Assoc. Professor Janelle Ayres, who specializes in the microbiome: If you care about health, you have to care about your microbiome. It touches on everything. #sdxcon2022 #sdbiotech

Janelle Ayres: The traditional view in how we think about bacteria is that they're bad... They're not bad. What we're doing to (bacteria) is bad. Our high fat diet. Our heavy reliance on antibiotics. Caring about the microbiome means taking a new approach. #sdxcon2022 @xconomy

John Mendlein at San Diego Life Sciences 2022: How do you take the power of a drug that changes medicine and keep the power in San Diego? That's how you grow the ecosystem even more than it has today? Xconomy #sdxcon2022

John Mendlein: We have some companies today that have the potential to change our ecosystem. Neurocrine Biosciences is one. aTyr Pharmaceuticals is another.

How fracking disrupted industrial biotech. For Genomatica, innovations to make bio-based chemicals from renewable feedstocks is one thing. Building a sustainable business on such technology is something else altogether. bit.ly/2DPUMCY

Organizing this afternoon summit in San Diego: bit.ly/2FCY2P8

$ARCT Like artillery barrage ahead of battle, ARCT board files lawsuit against fired CEO in advance of 5/7 proxy fight. Suit details allegations of ex-CEO's pattern of deceit and misconduct. He notes board's "pattern of disparagement. bit.ly/2GJcNEE

Bbigelow@xconomy

#scootersbehavingbadly Controversies over bike sharing, electric scooters illustrate why local govt struggles to keep up w/ digital innovation bit.ly/2FzDC9A

$ARCT Struggle for control at preclinical biotech Arcturus Therapeutics is now a full-blown legal battle bit.ly/2rlmHTU

A year after Intel $INTC closed its $15.3B buyout of Mobileye, Israeli autonomous tech company wants industry to adopt its "rules of the road" for self-driving cars, based on its mathematical model of what "safety" means to self-driving car.

Transcript of my exclusive interview with Dr. Jeffrey Lewis

Bloom Science sets out to advance mind-altering microbes for treating Epilepsy bit.ly/2IN9J89